human reproduction   **SUPPLEMENTARY DATA**

Supplementary Table SIX Association of SNPs with continuous log-transformed AMH-levels in the discovery VEVO cohort in women aged 18–40 at time of study (n = 270).

Gene	Variant	Position	Model	Variant, interaction term	Beta (SE) logAMH	P-value
BRSK1	**rs11668344**	55833664	1	rs11668344	0.08 (0.04)	0.057
				CED: 0	0 (ref)	
				− >0–4000	−0.05 (0.07)	0.474
				− ≥4000–8000	−0.29 (0.08)	0.000
				− ≥8000	−0.30 (0.09)	0.001
				Hormones	−0.29 (0.06)	0.000
			2	rs11668344	0.11 (0.07)	0.112
				CED: 0	0 (ref)	
				− >0–4000	−0.04 (0.10)	0.715
				− ≥4000–8000	−0.29 (0.12)	0.014
				− ≥8000	−0.16 (0.13)	0.207
				SNP*CED: 0	0 (ref)	
				− >0–4000	−0.02 (0.10)	0.876
				− ≥4000–8000	−0.03 (0.12)	0.977
				− ≥8000	−0.19 (0.13)	0.147
				Hormones	−0.29 (0.06)	0.000
FANCI	**rs1054875**	89879126	1	rs1054875	0.002 (0.04)	0.961
				CED: 0	0 (ref)	
				− >0–4000	−0.05 (0.07)	0.508
				− ≥4000–8000	−0.29 (0.08)	0.000
				− ≥8000	−0.29 (0.09)	0.001
				Hormones	−0.28 (0.06)	0.000
			2	rs1054875	0.11 (0.08)	0.135
				CED: 0	0 (ref)	
				− >0–4000	0.074 (0.10)	0.474
				− ≥4000–8000	−0.22 (0.11)	0.058
				− ≥8000	−0.16 (0.12)	0.175
				SNP*CED: 0	0 (ref)	
				− >0–4000	−0.18 (0.11)	0.102
				− ≥4000–8000	−0.11 (0.12)	0.356
				− ≥8000	−0.21 (0.13)	0.111
				Hormones	−0.28 (0.06)	0.000

AMH, anti-Müllerian hormone in μg/L; CED, cyclophosphamide equivalent dose in mg/m^2; SNP, single-nucleotide polymorphism; VEVO, DCOG-LATER VEVO cohort.
Position based on position build 37 on https://www.ncbi.nlm.nih.gov/snp/. Alt is coded. Model 1: adjusted for principal components, hormone usage, CED score in four categories, and age at time of study. Model 2: additional to Model 1 interaction term of variant*CED category.